Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity
Pharmaceutics · 23.06.2025 · 17 (7) · 811
DOI: 10.3390/pharmaceutics17070811 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 23.06.2025. Verfasst von Ahmed A Katamesh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Ha'il, Saudi Arabia, Scientific Research Deanship at the University of Ha’il, Saudi Arabia.
Abstract (Originalsprache)
Background
Olanzapine (Ola) is a second-generation antipsychotic with clinical utility limited by poor brain bioavailability due to blood–brain barrier restriction, hepatic first-pass metabolism, and systemic side effects. This study aimed to develop and optimize a novel intranasal polymersome-based nanocarrier (PolyOla) to enhance brain targeting, therapeutic efficacy, and safety of Ola.
Methods
PolyOla was prepared using poloxamer 401 and optimized through a Box–Behnken Design to minimize particle size and maximize entrapment (EE%) and loading efficiency (LE%). The formulation was characterized by size, morphology, drug release, and serum stability. In vivo studies in adult male Sprague-Dawley rats assessed pharmacokinetics (plasma and brain concentrations), pharmacodynamic efficacy in a ketamine-induced schizophrenia model, and systemic safety markers including metabolic, hepatic, and testicular oxidative stress indicators.
Results
Optimized PolyOla exhibited a particle size of 78.3 ± 4.5 nm, high EE% (91.36 ± 3.55%), and sustained in vitro drug release. It remained stable in serum for 24 h. Intranasal administration significantly improved brain delivery of Ola, achieving a 2.7-fold increase in Cmax and a 5.7-fold increase in AUC compared to oral dosing. The brain Tmax was 15 min, with high drug-targeting efficiency (DTE% = 365.38%), confirming efficient nose-to-brain transport. PolyOla-treated rats showed superior antipsychotic performance, reduced extrapyramidal symptoms, and improved systemic safety evidenced by mitigated weight gain, glycemic control, normalized liver enzymes, and reduced oxidative stress.
Conclusions
PolyOla offers a safe and effective intranasal delivery platform for Ola, enabling targeted brain delivery and improved management of schizophrenia with reduced peripheral toxicity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
- Department of Pharmaceutics, Faculty of Pharmacy, University of Sadat City, Menoufia 32897, Egypt.
- Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Jadara University, Irbid 21110, Jordan.
- Department of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
- Medical and Diagnostic Research Centre, University of Ha'il, Ha'il 55473, Saudi Arabia.
- Department of Pharmacology, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
ORCID-Profile: Ahmed A Katamesh, Hend Mohamed Abdel-Bar, Rania Mahafdeh, Mohammed Khaled Bin Break, Shimaa M Hassoun, Gehad M Subaiea, Mostafa E El-Naggar, Khaled Almansour, Hadel A Abo El-Enin
Förderung
- University of Ha'il, Saudi Arabia
- Scientific Research Deanship at the University of Ha’il, Saudi Arabia
Zitieren
APA
Katamesh, A. A., Abdel-Bar, H. M., Mahafdeh, R., Bin Break, M. K., Hassoun, S. M., Subaiea, G. M., El-Naggar, M. E., Almansour, K., Abo El-Enin, H. A., & Yassin, H. A. (2025). Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity. Pharmaceutics, 17(7), 811. https://doi.org/10.3390/pharmaceutics17070811
Vancouver
Katamesh AA, Abdel-Bar HM, Mahafdeh R, Bin Break MK, Hassoun SM, Subaiea GM, et al. Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity. Pharmaceutics. 2025;17(7):811. doi:10.3390/pharmaceutics17070811
BibTeX
@article{Katamesh2025,
author = {Katamesh, Ahmed A and Abdel-Bar, Hend Mohamed and Mahafdeh, Rania and Bin Break, Mohammed Khaled and Hassoun, Shimaa M and Subaiea, Gehad M and El-Naggar, Mostafa E and Almansour, Khaled and Abo El-Enin, Hadel A and Yassin, Heba A},
title = {Tunable Intranasal Polymersome Nanocarriers Triggered Olanzapine Brain Delivery and Improved In Vivo Antipsychotic Activity},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {7},
pages = {811},
doi = {10.3390/pharmaceutics17070811}
}
EUVIMED